Literature DB >> 9007854

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.

I Ciric1, A Ragin, C Baumgartner, D Pierce.   

Abstract

OBJECTIVE: The primary objectives of this report were, first, to determine the number and incidence of complications of transsphenoidal surgery performed by a cross-section of neurosurgeons in the United States and, second, to ascertain the influence of the surgeon's experience with the procedure on the occurrence of these complications. The secondary objective was to review complications of transsphenoidal surgery from the standpoint of their causation, treatment, and prevention.
METHODS: Questionnaires regarding 14 specific complications of transsphenoidal surgery were mailed to 3172 neurosurgeons. The data reported were analyzed from the 958 respondents (82%) who reported performing the operation. The neurosurgeons surveyed were asked to estimate the number of transsphenoidal operations performed, to identify any complications observed, and to estimate the percentage of operations that had resulted in any of the 14 specific complications. The 958 respondents were placed into three experience groups, based on the number of transsphenoidal operations performed. The data were analyzed by using chi 2 tests and Spearman correlation coefficients. The secondary objectives were met through a detailed review of the literature, in light of our experience.
RESULTS: Of the respondents, 87.3% reported having performed < 200 operations and 9.7% reported 200 to 500 previous operations. The remaining 3% reported more than 500 previous operations. More extensive previous experience with transsphenoidal surgery was associated with a greater likelihood of having witnessed each specific complication. The mean operative mortality rate for all three groups was 0.9%. Anterior pituitary insufficiency (19.4%) and diabetes insipidus (17.8%) were complications with the highest incidence of occurrence. The overall incidence of cerebrospinal fluid fistulas was 3.9%. Other significant complications, such as carotid artery injuries, hypothalamic injuries, loss of vision, and meningitis, occurred with incidence rates between 1 and 2%. An inverse relationship was found between the experience group and the likelihood of complications, as indicated by significant negative Spearman correlation coefficients for all but 2 of the 14 complications listed in the survey (P < 0.05). Thus, increased experience with transsphenoidal surgery seems to be associated with a decreased percentage of operations resulting in complications. Some caution should be exercised in interpreting these data, because they are based on the respondents' estimates.
CONCLUSION: Transsphenoidal surgery seems to be a reasonably safe procedure, with a mortality rate of less than 1%. However, a significant number of complications do occur. The incidence of these complications seems to be higher, with statistical significance, in the hands of less experienced surgeons. The learning curve seems to be relatively shallow, because a statistically significantly decreased incidence of morbidity and death could be documented after 200 and even 500 transsphenoidal operations. Better understanding of the indications for transsphenoidal surgery and improved familiarity with the regional anatomy should further lower the incidence of death and morbidity resulting from this procedure in the hands of all neurosurgeons.

Entities:  

Mesh:

Year:  1997        PMID: 9007854     DOI: 10.1097/00006123-199702000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  185 in total

1.  Vascular complications of transsphenoidal surgery.

Authors:  E R Laws
Journal:  Pituitary       Date:  1999-08       Impact factor: 4.107

Review 2.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Serial MR intensity changes of the posterior pituitary in patients with diabetes insipidus after transsphenoidal surgery for pituitary adenomas: report of two cases.

Authors:  Koichi Fukino; Shozo Yamada; Takahiro Ohta; Koji Takada; Masaaki Usui
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 4.  Complications of endoscopic surgery of the pituitary adenomas: analysis of 570 patients and review of the literature.

Authors:  Mustafa Berker; Derya Burcu Hazer; Taşkın Yücel; Alper Gürlek; Ayşenur Cila; Mustafa Aldur; Metin Onerci
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

5.  Spontaneous healing of iatrogenic direct carotid cavernous fistula.

Authors:  H-J Kwon; S-C Jin
Journal:  Interv Neuroradiol       Date:  2012-06-04       Impact factor: 1.610

6.  Prophylactic antibiotic trends in transsphenoidal surgery for pituitary lesions.

Authors:  Andrew S Little; William L White
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

7.  Treatment of ruptured ICA during transsphenoidal surgery. Two different endovascular strategies in two cases.

Authors:  S B Ghatge; D B Modi
Journal:  Interv Neuroradiol       Date:  2010-03-25       Impact factor: 1.610

8.  Characterization of the anatomic location of the pituitary stalk and its relationship to the dorsum sellae, tuberculum sellae and chiasmatic cistern.

Authors:  Salih Gulsen; Ahmet Hakan Dinc; Melih Unal; Nergis Cantürk; Nur Altinors
Journal:  J Korean Neurosurg Soc       Date:  2010-03-31

9.  Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Samuel Shin; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

10.  Cerebrovascular complications and utilization of endovascular techniques following transsphenoidal resection of pituitary adenomas: a study of the Nationwide Inpatient Sample 2001-2010.

Authors:  Waleed Brinjikji; Giuseppe Lanzino; Harry J Cloft
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.